This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Yokukansan treatment of chronic renal failure patients receiving hemodialysis, with behavioral and psychological symptoms of dementia: an open-label study


Sumiyoshi, Hidenori, Mantani, Akio, Nishiyama, Satoshi, Fujiwaki, Soh, Ohta, Shoichiro, Masuda, Yoshikazu, Tomita, Youhei, Tarumoto, Naofumi, Yamawaki, Shigeto


The American Journal Of Geriatric Psychiatry: Official Journal Of The American Association For Geriatric Psychiatry, Volume: 21, No.: 11, Pages.: 1082-1085

Year of Publication



Objective: The efficacy and safety of yokukansan (YKS) for chronic renal failure (CRF) patients receiving hemodialysis with behavioral and psychological symptoms of dementia (BPSD) was evaluated.; Methods: Twelve CRF patients receiving hemodialysis with BPSD were recruited and 7.5 g of YKS powder was added to ongoing therapy with antipsychotics. Neuropsychiatric Inventory (NPI) criteria and Barthel Index before and after 4-week YKS treatment were compared.; Results: Analysis of the mean score for NPI revealed a significant improvement during the period of YKS administration (25.3 ± 17.6 versus 8.36 ± 4.46; p = 0.0069). The mean score for the Barthel Index showed no significant difference during the period of YKS administration. Mean level of serum potassium was still within the normal range. No subjects had severe adverse reactions necessitating discontinuation from the study.; Conclusion: Yokukansan significantly improved the symptoms of BPSD in CRF patients receiving hemodialysis without critical side effects.; Copyright © 2013. Published by Elsevier Inc.

Bibtex Citation

@article{Sumiyoshi_2013, doi = {10.1016/j.jagp.2011.06.001}, url = {}, year = 2013, month = {nov}, publisher = {Elsevier {BV}}, volume = {21}, number = {11}, pages = {1082--1085}, author = {Hidenori Sumiyoshi and Akio Mantani and Satoshi Nishiyama and Soh Fujiwaki and Shoichiro Ohta and Yoshikazu Masuda and Youhei Tomita and Naofumi Tarumoto and Shigeto Yamawaki}, title = {Yokukansan Treatment of Chronic Renal Failure Patients Receiving Hemodialysis, with Behavioral and Psychological Symptoms of Dementia: An Open-Label Study}, journal = {The American Journal of Geriatric Psychiatry} }


adverse effects, aged, antipsychotic agents, blood, chronic renal failure, complications, dementia, drug therapy, drug therapy combination, drugs chinese herbal, female, hemodialysis, humans, hyperkalemia, kidney failure chronic, male, neuropsychological tests, potassium, psychology, renal dialysis, therapeutic use, yokukansan

Countries of Study


Types of Dementia

Dementia (general / unspecified)

Types of Study

Before and After Study

Type of Outcomes

ADLs/IADLs, Behaviour


Hospital Outpatient Care

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Herbal remedies, vitamins, dietary supplements